You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

4885 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Dec 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
ODB - General Benefit
    dexamethasone
Apr 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
May 2022
Drug
Other Name(s): Imfinzi®
Apr 2024

Pages